We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Cambridge Cognition Holdings PLC | AQSE:COG.GB | Aquis Stock Exchange | Ordinary Share | GB00B8DV9647 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 45.50 | 42.00 | 49.00 | 45.50 | 45.50 | 45.50 | 0.00 | 06:56:11 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From May 2023 to May 2024
TIDMCOG
RNS Number : 8898O
Cambridge Cognition Holdings PLC
05 October 2023
5 October 2023
Cambridge Cognition Holdings Plc
("Cambridge Cognition", the "Group" or the "Company")
Issue of Warrants
Cambridge Cognition Holdings plc (AIM: COG), which develops and markets digital solutions to assess brain health, announces, further to the Company's announcement on 26 September 2023, that the Company has issued Claret European Specialty Lending Company III, S.à r.l. ("Claret") with warrants to subscribe for 722,565 new ordinary shares of 1 pence each in the capital of the Company ("Ordinary Shares") at an exercise price of 74.734p.
Enquiries
Cambridge Cognition Holdings Plc Tel: 012 2381 0700 Matthew Stork, Chief Executive Officer press@camcog.com Stephen Symonds, Chief Financial Officer Panmure Gordon (UK) Limited (NOMAD and Joint Tel: 020 7886 2500 Broker) (Corporate Finance) Freddy Crossley / Emma Earl / Mark Rodgers (Corporate Broking) Rupert Dearden Dowgate Capital Limited (Joint Broker) Tel: 020 3903 7715 David Poutney / James Serjeant IFC Advisory Ltd (Financial PR and IR) Tel: 020 3934 6630 Tim Metcalfe / Graham Herring / Zach Cohen cog@investor-focus.co.uk
About Cambridge Cognition
Cambridge Cognition is a technology company developing digital health products to better understand, detect and treat conditions affecting brain health. The Company's software products assess cognitive health in patients worldwide to improve clinical trial outcomes, identify and stratify patients early and improve global efficiency in pharmaceutical and healthcare industries.
For further information visit www.cambridgecognition.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
MSCBLBDGDXGDGXU
(END) Dow Jones Newswires
October 05, 2023 12:33 ET (16:33 GMT)
1 Year Cambridge Cognition Chart |
1 Month Cambridge Cognition Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
